Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Bayer HealthCare has achieved second milestone under its collaboration agreement with MorphoSys, following the commencement of a Phase 1 trial of oncology drug BAY 94-9343.
Subscribe to our email newsletter
The current BAY 94-9343 program is directed against the target molecule mesothelin.
BAY 94-9343, a HuCAL-derived antibody-drug conjugate, showed potent, targeted anticancer activity against mesothelin- expressing tumors in preclinical testing.